This site is intended for healthcare professionals

FDA approves Libtayo as first immunotherapy indicated for patients with advanced basal cell carcinoma.- Sanofi

Read time: 1 mins
Last updated:28th Jun 2021
Published:11th Feb 2021
Condition: Basal Cell Carcinoma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest